Powering smarter drug development with precision PK/PD and bioanalysis
May 20, 2025
At Pharmidex, we help drug developers move faster and smarter with high-quality PK/PD assessments and bioanalytical services across a range of therapeutic areas.
🔬 Our team combines:
- Bespoke In vivo PK/PD & CNS penetration studies
- Wild-type, immunodeficient & humanised rodent models
- Advanced platforms: LC-MS/MS, qPCR, ELISA
🧠 Whether you're working on CNS drugs, oncology assets, or rare disease therapies, we deliver high quality data to drive confident decisions from lead optimisation to IND-enabling studies.
✨ Need to evaluate:
- BBB penetration?
- Target tissue exposure?
- PK profiling of small molecules or biologics?
We’ve got you covered.
📨 Let’s talk see how Pharmidex can support your next breakthrough:
🌐 www.pharmidex.com
The Pharmidex team will be in London for London Life Sciences Week from the 16th. Janette Dalay Robertson and Ash Alavijeh will be attending a range of events across the week. We are looking forward to a busy week discussing all things life-science related. Get in touch if you’d like to meet with us during the week as we visit existing clients and stakeholders!
Our Head of Integrated Therapeutics and CNS, Dr. Stephen Mitchell , our Business Development Manager, Janette Dalay Robertson and our Senior Research Scientist in CNS, Jewel Ahmed will be there to engage with attendees, share insights and explore new collaborations driving innovation in Parkinson’s disease drug discovery and development. If you’re attending, don’t hesitate to reach out, they’ll be delighted to connect and discuss how Pharmidex’s integrated expertise can help move your research from concept to clinic.
We are delighted to share that Prof. Mo Alavijeh will be attending the upcoming 🔬 OBN (UK) Ltd BioTuesday: A Spotlight on the Latest R&D for the Diagnosis & Treatment of Prostate Cancer 📅 11 November 2025 📍 Ipsen, Paddington, London This event brings together leading experts and innovators shaping the future of prostate cancer research and therapy. If you’re attending, don’t miss the opportunity to meet with Prof. Mo Alavijeh (FRSC, FRSM), and explore how collaboration can accelerate progress in drug discovery and development.
